Compare iShares MSCI Australia ETF (EWA) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Australia ETF vs Tempus AI — how do they compare? iShares MSCI Australia ETF trades at $28.27 (market cap $1.19B), while Tempus AI trades at $70.5 (market cap $12.77B). The key difference: Tempus AI is far larger — about 10.7× iShares MSCI Australia ETF's market cap, and iShares MSCI Australia ETF is trading nearer its 52-week high, Tempus AI nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Australia ETF for 63 Days and Tempus AI for 22 Days on average.
| EWA | TEM | |
|---|---|---|
Market Cap | $1.19B | $12.77B |
Volume | 2,714,198 | 8,980,490 |
Sector | Broad Market / Factor | Broad Market / Factor |
52-Week High | $30.43 | $99.28 |
52-Week Low | $24.95 | $41.55 |
Typical Hold Time | 63 Days | 22 Days |
Enterprise Value | — | $13.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The iShares MSCI Australia ETF (EWA) trades at $28.23, down 1.12% amid bearish technical signals and mixed institutional activity. Recent news highlights Australia's stock market hitting three-month lows due to inflation concerns from rising oil prices, though some analysts see upside potential given the country's commodity-driven economy. Technical indicators show selling pressure with moving averages signaling bearish momentum while oscillators remain neutral.
EWA faces near-term headwinds from Australian market volatility and inflation worries, but long-term prospects remain tied to global commodity demand. The ETF's commodity exposure provides diversification benefits, though investors should monitor Australian economic conditions and Federal Reserve policy impacts. Risk-reward appears balanced with technical resistance at $29 and support at $28.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
